Yes Nidan and recall too back in December 2017 we discussed that:
• MS was newly discussed in the 2017 10-k (and not in 2016)
• MS was newly mentioned in the p/r on Monday 12/11/17
• Dr M reminded us about the positive & encouraging MS data from WSU testing during the 12/11/17 conf call
• Dr M stated in the December 2017 conference call that they were still moving forward with the MS indication and that updates would be available in 2018 “in the course of the coming year” when they have “better clarity”
• the MS indication was included in the September 2017 CNS Partner Summit abstract
I wonder if their clarity has been bettered by Dr Lisak’s newest conclusions and upcoming 10/10/18 ECTRIMS poster abstract; or by any discussions following the recent 2 year MTA anniversary with Biogen?
IMO Anavex’s SAB will recommend that we pursue this MS indication and a clinical trial in light of the 3rd party experts’ positive preclinical findings at ECTRIMS 2017 and now 2018.
Seems there should be available grants and funding available from the National MS Society or other foundations, right? We are talking about positive preclinical conclusions & a2-73 results from one of the top MS labs and researchers in the US, if not globally.
News 
Market Data 
Discover 
